Phoenix Tissue Repair, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2017-01-01
- Employees
- -
- Market Cap
- -
Extension Study to PTR-01-002 (A Study in Recessive Dystrophic Epidermolysis Bullosa (RDEB) Patients Previously Treated With PTR-01)
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2022-11-21
- Lead Sponsor
- Phoenix Tissue Repair, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT05143190
- Locations
- 🇺🇸
Columbia University Irving Medical Center, New York, New York, United States
🇺🇸Stanford University, Redwood City, California, United States
A Study of PTR-01 in Recessive Dystrophic Epidermolysis Bullosa
- First Posted Date
- 2020-10-23
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Phoenix Tissue Repair, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT04599881
- Locations
- 🇺🇸
Stanford University, Redwood City, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
A Phase 1/2 Trial of PTR-01 in Adult Patients With Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Phase 1
Completed
- Conditions
- Recessive Dystrophic Epidermolysis Bullosa
- Interventions
- Drug: Normal saline
- First Posted Date
- 2018-11-26
- Last Posted Date
- 2021-03-09
- Lead Sponsor
- Phoenix Tissue Repair, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT03752905
- Locations
- 🇺🇸
Stanford University, Redwood City, California, United States
🇺🇸Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸Thomas Jefferson Univeristiy, Philadelphia, Pennsylvania, United States
© Copyright 2025. All Rights Reserved by MedPath